Klaus Sindahl

Klaus Sindahl has a diverse work experience spanning over two decades. Klaus is currently the VP, Head of Investor Relations at Hansa Biopharma, a position they have held since 2019. Prior to this, they worked as the Business Development Director at Royal Unibrew in 2018. From 2006 to 2018, they were associated with Novozymes, where they held various roles including Senior Manager, Investor Relations, Project Manager & Executive Assistant, and Acquisition Manager. In 2006, they worked as an M&A Analyst at DSP Corporate Finance. Klaus began their career as a Project Controller at TDC in 2004 and worked as an Auditor at Ernst & Young from 2001 to 2003.

Klaus Sindahl has a diverse education history. Klaus obtained a Bachelor of Science degree in Business Administration & Accounting from Syddansk Universitet - University of Southern Denmark from 1998 to 2001. Prior to that, they attended Esbjerg Handelsskole from 1995 to 1998, although the details of their field of study are not provided. Subsequently, Klaus pursued a Master of Science degree in Finance at Copenhagen Business School from 2003 to 2006. Klaus then studied Chinese Politics & Economy at Fudan University in 2006 for a year. In 2010, Klaus attended ICAEW for a year and focused on the study of International Financial Reporting Standards (IFRS). Finally, they briefly attended MIT Sloan School of Management in 2011 to delve into Corporate Strategy, though the specific duration and degree information for this experience is not specified.